Disease relevance of Moraxella (Branhamella) catarrhalis

• In addition, beta-lactamase-producing isolates of Hemophilus influenzae, Branhamella catarrhalis, Neisseria gonorrhoeae, and Staphylococcus aureus were susceptible to ticarcillin and clavulanate [1].
• Lomefloxacin demonstrated inhibition (zones greater than or equal to 19 mm) of greater than 90% of Enterobacteriaceae, greater than 99% of Moraxella (Branhamella) catarrhalis, greater than 98% of Haemophilus spp., and 91% of Staphylococcus aureus strains [2].
• Antibiotic-resistant commensal strains of Neisseria spp. and Branhamella catarrhalis were isolated from throat cultures, on the basis of their capacity to grow in the presence of penicillin, streptomycin, or sulfamethoxazole-trimethoprim [3].
• Genetic basis of tetracycline resistance in Moraxella (Branhamella) catarrhalis [4].
• OPC-17116 had potent activity against important pathogens of respiratory tract infections such as Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, and Branhamella catarrhalis [5].

High impact information on Moraxella (Branhamella) catarrhalis

• Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid [6].
• RESULTS: Although intrinsically resistant to a small group of drugs that included vancomycin and trimethoprim, acquired drug resistance in Branhamella catarrhalis was unknown in the early years of antimicrobial therapy [7].
• Antibody response to P-protein in patients with Branhamella catarrhalis infections [8].
• Outer membrane protein E (OMP E) is a 50-kDa major OMP of Branhamella catarrhalis [9].
• Molecular characterization of the BRO beta-lactamase of Moraxella (Branhamella) catarrhalis [10].

Chemical compound and disease context of Moraxella (Branhamella) catarrhalis

• Inhibition of the beta-lactamases of Branhamella catarrhalis by clavulanic acid and other inhibitors [11].
• Disk diffusion susceptibility testing of Branhamella catarrhalis with ampicillin and seven other antimicrobial agents [12].
• Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis [13].
• LY163892 is less active than amoxicillin against streptococci and less active than amoxicillin-clavulanic acid against Branhamella catarrhalis but comparable against other pathogens [14].
• FR 17027 inhibited beta-lactamase-producing isolates of Neisseria gonorrhoeae, Haemophilus influenzae, and Branhamella catarrhalis at less than 0.1 micrograms/ml and was more active than cefaclor or cephalexin against these bacteria [15].

Biological context of Moraxella (Branhamella) catarrhalis

• No plasmid deoxyribonucleic acid was found in two strains of penicillinase-producing Branhamella catarrhalis, and these strains produced a penicillinase different from the TEM-1 enzyme [16].
• Evaluation of Bacto TB hydrolysis reagent (Tween 80) for the identification of Branhamella catarrhalis [17].
• Treatment of human splenic B lymphocytes with the mitogen Branhamella catarrhalis (BC) and transforming growth factor-beta 1 (TGF-beta 1) induces expression of germline Ig C alpha transcripts and class switching to this isotype [18].

Anatomical context of Moraxella (Branhamella) catarrhalis

• Clinical isolates of Branhamella catarrhalis from the sputum of 20 patients with acute bronchopulmonary infection were examined for synthesis of immunoglobulin A1 protease by immunoelectrophoresis [19].
• Effect of ampicillin, cefmetazole and minocycline on the adherence of Branhamella catarrhalis to pharyngeal epithelial cells [20].

Gene context of Moraxella (Branhamella) catarrhalis

• PISP and PRSP were frequently detected in children aged 5 years or younger. beta-Lactamase was produced by 96 of the 100 strains (96%) of Moraxella (Branhamella) catarrhalis [21].
• Lack of immunoglobulin A1 protease production by Branhamella catarrhalis [19].
• All 14 strains of Haemophilus influenzae and all 13 strains of Branhamella catarrhalis tested were positive with respect to plasminogen uptake [22].
• By employing the non-ionic detergent Triton X-100, a membrane-bound beta-lactamase was extracted from strains of Moraxella (Branhamella) catarrhalis and Moraxella nonliquefaciens that produce BRO-1 and BRO-2 beta-lactamases [23].
• Use of the API NeIdent system for identification of pathogenic Neisseria spp. and Branhamella catarrhalis [24].

Analytical, diagnostic and therapeutic context of Moraxella (Branhamella) catarrhalis

• Fifty strains of Branhamella catarrhalis were examined for susceptibility to sulphamethoxazole, trimethoprim and a combination of the two by determinating minimum inhibitory concentrations (MICs) and fractional inhibitory concentrations (FICs) [25].
• The polysaccharide of the Moraxella (Branhamella) catarrhalis serotype A lipopolysaccharide was prepared by mild acid hydrolysis followed by gel permeation chromatography [26].

References